Physician profile
Julia Buchfuhrer
NPI 1093179319
$308,454.08
in general payments reported to CMS, 2019-2025
41 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.56 · 2021: $1,175 · 2022: $8,995 · 2023: $15K · 2024: $85K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Travel and Lodging: $29K · Food and Beverage: $24K · Consulting Fee: $13K · Honoraria: $8,134 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $223,029.00 |
| Travel and Lodging | $29,120.72 |
| Food and Beverage | $24,236.13 |
| Consulting Fee | $13,323.60 |
| Honoraria | $8,133.50 |
| Education | $428.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $184,487.51 | 2021-2025 | Krystexxa, Evenity, Otezla |
| Abbvie INC. | $80,057.34 | 2021-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $23,372.12 | 2021-2025 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $9,745.38 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $1,672.68 | 2019-2025 | Benlysta, Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,454.48 | 2021-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $905.34 | 2022-2025 | Taltz, Zepbound, Mounjaro |
| Aurinia Pharma U.S., INC. | $811.86 | 2021-2025 | Lupkynis |
| Ucb, INC. | $551.53 | 2024-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $527.62 | 2021-2024 | Saphnelo |
| Ani Pharmaceuticals, INC. | $516.50 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $412.62 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $399.91 | 2023-2025 | Belbuca |
| Pfizer INC. | $388.60 | 2022-2025 | |
| Genzyme Corporation | $382.01 | 2021-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $376.48 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $356.30 | 2021-2025 | |
| Organon LLC | $321.83 | 2023-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $317.15 | 2023-2025 | Idacio |
| Sobi, INC | $220.88 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $142.11 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $125.97 | 2024-2025 | Lumryz |
| Radius Health, INC. | $107.79 | 2024-2025 | Tymlos |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $92.75 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $71.51 | 2022-2025 | Gazyva |
| Scilex Pharmaceuticals INC. | $69.87 | 2024 | |
| Depuy Synthes Sales INC. | $66.74 | 2021-2023 | Orthovisc, Monovisc |
| E.R. Squibb & Sons, L.L.C. | $61.83 | 2021-2022 | |
| United Therapeutics Corporation | $51.45 | 2022-2024 | Tyvaso |
| Electromed, INC. | $42.31 | 2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $38.36 | 2023-2024 | Acthar |
| Bioventus LLC | $35.34 | 2021-2022 | |
| Sandoz INC. | $33.21 | 2025 | Hyrimoz |
| Azurity Pharmaceuticals, INC. | $30.59 | 2025 | Horizant |
| Paratek Pharmaceuticals, INC. | $22.72 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $22.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.91 | 2022 | |
| Baxter Healthcare | $15.07 | 2023 | Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $13.06 | 2023 | |
| Puma Biotechnology, INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Buchfuhrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.